Disaggregated Revenues (Tables)

3 Months Ended

Mar. 31, 2025

Disaggregation of Revenue [Abstract]

Schedule of Disaggregation of Revenues

The following table provides information regarding total revenues (dollars in thousands):

	Three Months Ended March 31,
	2025		2024
	(unaudited)
Net product sales
Qelbree	$	64,745	$	45,104
GOCOVRI	30,689		26,562
APOKYN	14,976		16,649
Trokendi XR	12,801		15,989
Oxtellar XR	10,198		26,943
Other(1)	8,579		7,214
Total net product sales	141,988		138,461
Royalty, licensing and other revenues	7,836		5,183
Total revenues	$	149,824	$	143,644

___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.